Skip to content

Norepinephrine Prevent Post-induction Hypotension in High-risk Patients

Continuous Norepinephrine Infusion Before General Anesthesia to Prevent Post-induction Hypotension in High-risk Patients Undergoing Major Noncardiac Surgery

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06028256
Enrollment
180
Registered
2023-09-08
Start date
2023-10-01
Completion date
2024-10-01
Last updated
2023-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Blood Pressure, Norepinephrine

Keywords

intraoperative hypotension, arterial pressure, general surgery, general anesthesia, noncardiac surgery

Brief summary

The investigators aimed to investigate the effects of continuous infusion of norepinephrine before and after general anesthesia induction on the occurrence of post-induction hypotension.

Detailed description

Intraoperative hypotension is common after general anesthesia induction and is associated with adverse postoperative events. Norepinephrine is one of the most applied vasopressors in clinical to treat intraoperative hypotension. Due to the absence of effective measures for predicting intraoperative hypotension, infusing norepinephrine before and during anesthesia induction may reduce intraoperative hypotension. There is currently a lack of research regarding whether continuous norepinephrine infusion before and during the induction of general anesthesia can mitigate or prevent post-induction hypotension. The investigators aim to investigate the effects of continuous infusion of norepinephrine before and after general anesthesia induction on the occurrence of post-induction hypotension.

Interventions

DRUGNorepinephrine Hydrochloride

Both arms of patients will receive standard anesthesia and surgical management. Radial artery cannulation and invasive blood pressure monitoring will be perform. Norepinephrine will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.

DRUGPlacebo

Normal saline will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.

Sponsors

First Affiliated Hospital of Kunming Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged above 65 years or those above 45 years with at least one of the following preoperative cardiovascular diseases: essential hypertension, coronary artery disease, stroke, or type I/II diabetes mellitus. * Patients who will receive major noncardiac surgery as open or laparoscopic abdominal surgeries with an anticipated operative duration over two hours, including gastrointestinal, liver, pancreatic, bladder, and uterine/adnexal surgeries.

Exclusion criteria

* Patients who declined to participate in the present study. * Patients enrolled in another ongoing clinical study. * Patients with systolic arterial pressure (SAP) below 90 mmHg or above 160 mmHg, or heart rate (HR) over 100 beats per minute (bpm) before anesthesia induction. * Patients who have experienced any type of shock within 30 days before surgery. * Patients with circulatory instability require continuous or intermittent positive inotropic and/or vasopressors within 24 hours before surgery. * Patients receive continuous or intermittent intravenous antihypertensive agents within 24 hours before surgery. * Patients underwent coronary artery bypass grafting, coronary angiography, or coronary stenting within 180 days before surgery. * Patients who were diagnosed with new-onset tachyarrhythmia within 180 days before surgery, such as atrial fibrillation, atrial flutter, and premature ventricular contractions. * Patients with preoperative alanine aminotransferase \>80 international units and/or glomerular filtration rate \< 80 ml/min within the 180 days before surgery. * Patients are ineligible for intraoperative invasive radial artery blood pressure monitoring. * Patients with a known history of allergy to norepinephrine. * Patients who were planned for rapid sequence induction. * Patients who were scheduled for awake tracheal intubation. * Patients who were scheduled for double-lumen endotracheal intubation. Pregnant or lactating patients.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of post-induction hypotensionFrom induction of general anesthesia to skin incision (up to one hour from induction of general anesthesia)Hypotension: mean arterial pressure (MAP) \<65 mmHg

Secondary

MeasureTime frameDescription
Incidence of the following abnormal vital signsFrom induction of general anesthesia to skin incision (up to one hours from induction of general anesthesia)MAP\<65 mmHg, MAP\<55 mmHg, MAP decreased over 20% ,30% and 40% from preoperative level; MAP increased over 20%, 30%, and 40% from preoperative level; SAP \< 90 mmHg; Systolic arterial pressure (SAP) \> 160 mmHg; Heart rate (HR) \< 40 bpm, HR \> 100 bpm; dosage of norepinephrine given by anesthesiologists; amount of fluid; the time-point of the first events of MAP \< 65 mmHg, MAP \< 55 mmHg, SAP \< 90 mmHg, SAP \> 160 mmHg, MAP increased over 20%, 30%, and 40% from preoperative level.
Postoperative major adverse cardiac eventsWithin 30 days after surgeryCardiac death, myocardial infarction, on-fatal cardiac arrest, coronary revascularization

Contacts

Primary ContactYuan Chang
changyuan@ydyy.cn+86 0871 65324888
Backup ContactJianlin Shao
shaojlL@ydyy.cn

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026